Mirapexin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole dihydrochloride monohydrate, the active ingredient in Mirapexin, is a dopamine agonist presented as oral tablets for oral administration. It provides symptomatic relief in Parkinson's disease and Restless Legs Syndrome by stimulating dopamine D2/D3 receptors in the central nervous system of adult patients.

GNH USA supplies Mirapexin as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies, transplant centres and clinics worldwide under strict quality standards. All batches conform to European Union pharmacopeial specifications and are manufactured in GMP‑certified facilities.

Mirapexin is a dopamine agonist used in the treatment of movement disorders that involve dopaminergic deficiency. - Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia. - Restless Legs Syndrome: reduces the urge to move the legs and associated discomfort. - Parkinson's disease motor fluctuations: helps decrease “off” periods and prolong “on” time.

Pramipexole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness or imbalance. - Somnolence: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Hallucinations: visual or auditory perceptual disturbances. - Impulse control disorders: compulsive gambling, shopping or eating. - Sudden onset of sleep: unexpected episodes of falling asleep.

When prescribing Mirapexin, clinicians should consider several precautionary measures to ensure safe use. - Dose titration: start with a low dose and increase gradually to minimize adverse effects. - Renal impairment: adjust dosage according to renal function, especially in severe impairment. - Elderly patients: monitor for excessive somnolence and orthostatic hypotension. - Psychiatric symptoms: observe for hallucinations, depression or impulse control changes. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Pramipexole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO‑B inhibitors: combined use may increase risk of hypertensive crisis. - Antipsychotics (D2 antagonists): may reduce the therapeutic effect of pramipexole. - Strong CYP2D6 inhibitors: can raise pramipexole plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure‑lowering effect may cause hypotension. - Alcohol: may enhance central nervous system depression and somnolence. - Other dopamine agonists: concurrent use can increase the likelihood of side effects.